Attention deficit hyperactivity disorder

• 1. Introduction

  ›

  Attention deficit hyperactivity disorder, known as ADHD, sits at the extreme lower end of a continuous bell curve of executive functioning that every human being falls somewhere on. That framing matters: ADHD is not a separate category of broken minds but the tail end of a trait the entire population shares. What separates someone with ADHD from someone without it is degree, not kind. And the consequences of sitting at that tail are severe. Impairments in time management, cognitive inhibition, task initiation, and sustained attention can reduce life expectancy, not just quality of life. A heritability rate of 70 to 80 percent makes it primarily a genetic condition, yet its causes in any individual case remain largely unknown. Its three core presentations, each with distinct patterns of inattention, hyperactivity, and impulsivity, manifest differently across genders, across the lifespan, and across cultures. This documentary explores what ADHD actually is, what happens inside the brain that drives it, how clinicians struggle to pin it down, and what can be done about it.

• 2. What ADHD Actually Feels Like

  ›

  About half of children and adolescents with ADHD face social rejection from their peers, compared to 10 to 15 percent of those without the disorder. That gap in belonging is an early and persistent cost. People with attention deficits may drift off mid-conversation, miss social cues, and struggle to learn social norms that others absorb without trying. The three presentations of ADHD each wear a different face. The predominantly inattentive type is marked by overlooking details, losing items, forgetting daily activities, and being easily pulled into internal thoughts. The predominantly hyperactive-impulsive type shows as fidgeting, excessive talking, difficulty waiting a turn, and a constant impulse to act before thinking. Girls with ADHD tend to display fewer hyperactivity symptoms and more inattention, which gets interpreted as being spacey or forgetful rather than as a clinical condition, delaying or preventing diagnosis. Hyperactivity does not vanish with age; it migrates inward. In teenagers and adults it becomes a sense of physical restlessness, an inability to relax, and constant mental activity. Impulsivity in adulthood surfaces as thoughtless spending, sensation-seeking, and impatience. A 2025 study found that 41.1 percent of women with ADHD also experience premenstrual dysphoric disorder, compared to 9.8 percent in a non-ADHD reference group, linking the hormonal cycle to symptom fluctuation. One of the most discussed but least formally recognized features of ADHD is hyperfocus: an intense, narrow concentration on a single task for a prolonged period. Studies published in 2016, 2019, and 2024 found that people with ADHD experience hyperfocus more often or more acutely. It is linked to flow and also to perseveration, and it carries real risks including internet addiction and certain types of offending behaviour. Mind wandering is a related phenomenon. The European Consensus Statement on ADHD diagnosis and treatment, published in 2019, identified mind wandering as a strong predictor of adult ADHD, potentially even more predictive than the classic symptoms of inattention or hyperactivity. Research shows that elevated mind wandering can be detected as early as kindergarten, where it predicts weaker arithmetic and phonological performance.

• 3. A Brain Built Differently

  ›

  The dopamine and norepinephrine pathways that originate in the ventral tegmental area and locus coeruleus govern much of what goes wrong in ADHD. These pathways project to the prefrontal cortex and striatum, the regions responsible for executive control, motivation, reward perception, and motor function. In children with ADHD, brain imaging shows a general reduction in the volume of certain structures, with a proportionally greater decrease in the left-sided prefrontal cortex. The subcortical volumes of the accumbens, amygdala, caudate, hippocampus, and putamen all appear smaller than in controls. Functional MRI studies have found higher connectivity between subcortical and cortical regions, and the degree of that hyperconnectivity correlates with the severity of inattention or hyperactivity. PET mapping has revealed that the distribution of mu-opioid receptors is the strongest contributor to cortical abnormalities in ADHD, followed by CB1 cannabinoid receptors. The ADHD brain is not simply a dopamine-deficient brain. There may additionally be abnormalities in serotonergic, glutamatergic, or cholinergic pathways. People with ADHD appear to have unimpaired long-term memory; deficits in long-term recall trace back to working memory failures rather than any storage problem. On IQ tests, the most affected sub-tasks in ADHD are the Arithmetic and Digit Span tasks on the WAIS. The WAIS and WISC have attempted to account for this by introducing substitute scoring systems that only count sub-tests robust against executive dysfunction. On the Stanford-Binet, youth with ADHD take longer to complete the test and show widespread irregularities within working memory sub-tests. A common variant of a gene called latrophilin 3 is estimated to account for about 9 percent of cases, and people carrying that variant are particularly responsive to stimulant medication.

• 4. The Genetics Behind It

  ›

  Literature reviews published in Biological Psychiatry and Molecular Psychiatry found the average heritability estimate of ADHD to fall between 0.74 and 0.8, based on family, twin, and adoption studies. Siblings of children with ADHD are three to four times more likely to develop the disorder than siblings of children without it. No single gene predicts ADHD; it is polygenic, arising through the accumulation of many genetic risk factors each contributing a very small effect. Among the genes most closely associated with the condition are those involved in dopamine signalling, including DAT, DRD4, DRD5, TAAR1, MAOA, COMT, and DBH, as well as SERT, HTR1B, SNAP25, GRIN2A, ADRA2A, TPH2, and BDNF. The DRD4-7R variant of dopamine receptor D4 causes increased inhibitory effects induced by dopamine, produces a wide range of behavioural phenotypes including ADHD symptoms, and is linked to novelty seeking. The genes GFOD1 and CDH13 show strong genetic associations with ADHD; CDH13's involvement also in autism spectrum disorder, schizophrenia, bipolar disorder, and depression makes it a candidate of particular interest. In zebrafish, knockout of the gene ADGRL3 causes a loss of dopaminergic function in the ventral diencephalon, and the fish display a hyperactive-impulsive phenotype, a telling animal model of the human condition. Natural selection has been acting against genetic variants for ADHD for at least 45,000 years. Evolutionary theorists have proposed that traits such as novelty-seeking, rapid task-switching, and high exploratory drive may have been cognitive specialisations well suited to ancestral forager-gatherer environments. Evolutionary psychiatrist Randolph M. Nesse has pointed to the approximately 5:1 male-to-female sex ratio in ADHD epidemiology as suggestive of a distribution pattern, citing clinical psychologist Simon Baron-Cohen's similar observations about autism, where males are overrepresented at the tails of a continuum.

• 5. Diagnosing Something Invisible

  ›

  According to DSM-5 criteria, a child under 17 must show at least six symptoms of either inattention or hyperactivity-impulsivity, present for six months or more, across at least two settings, with onset of several symptoms before age 12. For those 17 and older, the threshold drops to five symptoms. Diagnosis is not made through a blood test or a brain scan. Imaging studies do not produce consistent results between individuals, and a 2024 systematic review concluded that the use of biomarkers, EEG markers, and neuroimaging for ADHD diagnosis remains unclear. The most commonly used rating scales in children are the Achenbach System of Empirically Based Assessment tools, including the Child Behavior Checklist for parents, the Youth Self Report Form for children, and the Teacher Report Form for teachers. A 2024 meta-analysis commissioned by the Patient-Centered Outcomes Research Institute found that rating scales based on parent, teacher, or adolescent self-report show high internal consistency, but the reliability between raters is only poor to moderate. Diagnosis skews along socioeconomic and racial lines. Most diagnoses in children occur in low-income families, and Caucasian children receive diagnoses more often than Black, Hispanic, and Asian children, a gap that may reflect racial and socioeconomic biases in how symptoms are interpreted rather than true differences in prevalence. Thomas Szasz, a prominent critic, argued that ADHD was invented and then given a name. The International Consensus Statement on ADHD responded that this criticism is unfounded, citing two pillars: well-trained clinicians across settings and cultures agree on its presence using well-defined criteria, and the diagnosis reliably predicts future problems, treatment response, and a consistent set of biological findings. In North America and Australia, DSM-5 is used for diagnosis; European countries typically use ICD-11, where ADHD carries the code 6A05.

• 6. The Weight of Comorbidities

  ›

  Data collected in 2022 by the U.S. Centers for Disease Control and Prevention found that nearly 78 percent of children with ADHD have at least one other co-occurring condition. Autism spectrum disorder co-occurs in about 21 percent of people with ADHD. Learning disabilities appear in 20 to 30 percent of children with ADHD. Oppositional defiant disorder occurs in about 25 percent of children with an inattentive presentation and 50 percent of those with a combined presentation. Conduct disorder appears in 25 percent of individuals with combined presentation, and adolescents who carry both diagnoses are more likely to develop antisocial personality disorder in adulthood. Systematic reviews in 2017 and 2020 found strong evidence that ADHD is associated with increased suicide risk across all age groups. A 2019 meta-analysis found that the prevalence of suicide attempts in individuals with ADHD was 18.9 percent, compared to 9.3 percent in individuals without ADHD. Individuals with ADHD are three times more likely to be diagnosed with an eating disorder than those without ADHD; conversely, individuals with eating disorders are twice as likely to have ADHD. A January 2014 meta-analysis of 16 studies found that drivers with ADHD face a relative risk of traffic collisions of 1.36, rising to 1.86 for ADHD drivers who also have oppositional defiant disorder or conduct disorder. A systematic review published in Neuroscience & Biobehavioral Reviews in June 2021, drawing on 82 studies, confirmed elevated accident-proneness in ADHD patients and found that the type and overall risk of injury changes across the lifespan. Sleep disorders are a particularly tangled comorbidity: they can be a feature of ADHD itself, a side effect of ADHD medications, or an independent condition that mimics ADHD symptoms. Insomnia is the most common sleep disorder in children with ADHD, with behavioural therapy as the preferred treatment.

• 7. Treatment: What Works

  ›

  About 70 percent of people with ADHD respond to the first stimulant medication tried. As few as 10 percent respond to neither amphetamines nor methylphenidate. Methylphenidate and amphetamine or its derivatives are typically the first-line treatments. A 2018 review found the greatest short-term benefit with methylphenidate in children and with amphetamines in adults. Studies and meta-analyses show that amphetamine is slightly to modestly more effective than methylphenidate at reducing symptoms overall. MRI studies suggest that long-term treatment with either medication can decrease abnormalities in brain structure and function found in people with ADHD. One systematic review summarised the evidence this way: pharmacological treatment of ADHD is associated with increased achievement and decreased absenteeism at school, a reduced risk of trauma-related emergency hospital visits, reduced risks of suicide and attempted suicide, and decreased rates of substance abuse and criminality. Despite that evidence, a Cochrane meta-review by Dr Storebø and colleagues raised doubts about methylphenidate's efficacy relative to placebo, prompting a strong critical response from the European ADHD Guidelines Group. Since at least September 2021, there is a unanimous global scientific consensus that methylphenidate is safe and highly effective for treating ADHD. In 2020, the FDA granted marketing authorisation to AKL-T01, marketed as EndeavorRx, a video game-based digital therapeutic developed by Akili Interactive Labs, making it the first game-based therapeutic granted such authorisation for any condition. A 2023 study in the Journal of the American Academy of Child & Adolescent Psychiatry found that after six weeks of at-home treatment with AKL-T01, adults showed improvements in objective attention measures, reported symptoms, and quality of life, with the magnitude of attention improvement nearly seven times greater than that reported in paediatric trials. Behavioural therapies remain the recommended first-line treatment for preschool-aged children and those with mild symptoms, and stable, high-quality friendships with non-deviant peers are specifically protective against later psychological problems.